Abstract

* The labeling of two drugs used in the treatment of type 2 diabetes—canagliflozin and dapagliflozin—has been revised to strengthen the warning concerning possible kidney damage. The labels now state that acute kidney injury is possible with use of the drugs. * The labeling revision is based on a Food and Drug Administration review of 101 case reports of patients who developed acute renal injury while taking one of these drugs. The majority of patients required hospitalization and four died.